NASDAQ$ETNB
89Bio Inc · Q4 2020 earnings
Q4 2020 earnings · · Investor relations
Briefing
89bio reported financial results for Q4 and full year 2020 and provided a corporate update.
89bio reported cash, cash equivalents, and short-term investments totaling $204.7 million as of December 31, 2020. R&D expenses were $8.8 million for the three months ended December 31, 2020, and G&A expenses were $3.8 million for the same period. The company anticipates important clinical milestones in 2021 to validate BIO89-100's potential in NASH and SHTG.
- Presented updated clinical data from Phase 1b/2a study of BIO89-100 in NASH at AASLD’s The Liver Meeting® 2020 and at ENDO 2021.
- Initiate the Phase 2b trial in NASH patients in the first half of 2021.
- Report topline data from the paired-biopsy, open-label histology cohort in NASH patients by year-end 2021.
- Report topline data from the Phase 2 ENTRIGUE study of BIO89-100 in SHTG patients in the second half of 2021.
Headline financials
Revenue & EPS history
89Bio · Revenue · Quarterly
$0
Forward guidance
89bio anticipates several clinical milestones in 2021, including the initiation of a Phase 2b NASH trial and topline data reports from NASH histology cohort and Phase 2 SHTG trial.
Tailwinds
- Initiation of BIO89-100 Phase 2b NASH trial planned in 1H21
- NASH histology cohort topline data expected by YE21
- Phase 2 SHTG trial (ENTRIGUE) expected to report topline data in 2H21
- BIO89-100's compelling efficacy profile and favorable tolerability with weekly and every two-week dosing confirmed
- Significant reductions in liver volume and liver fat volume at 13 weeks compared to baseline in treated patients
Headwinds
- Reliance on forward-looking statements based on current estimates and assumptions
- Various risks and uncertainties could cause actual results to be materially different
- Uncertainties regarding the timing and outcome of the Phase 2b trial in NASH
- Potential effect of the COVID-19 pandemic on clinical trials and business operations
- Impact of general economic, health, industrial or political conditions
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 7 quarterly earnings reports
-0.1%
Avg return
Earnings day
-4.6%
Avg return
5 days after
-2.8%
Avg return
30 days after
54%
13 / 24 earnings
Positive
+14.8%
Q4 2019
Best reaction
-19.4%
Q1 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | — | — | — | |
| Q2 2025 | +1.7% | +1.3% | -1.7% | |
| Q1 2025 | -3.7% | -4.1% | +18.6% | |
| Q4 2024 | -1.0% | -7.1% | -3.7% | |
| Q3 2024 | +2.8% | -10.9% | -20.6% | |
| Q2 2024 | -10.9% | -11.8% | -0.9% | |
| Q1 2024 | -3.5% | +0.8% | -10.2% | |
| Q4 2023 | +7.3% | -0.2% | -1.3% | |
| Q3 2023 | -11.8% | — | — | |
| Q2 2023 | +5.3% | — | — | |
| Q1 2023 | +1.3% | — | — | |
| Q4 2022 | -1.1% | — | — | |
| Q3 2022 | +14.2% | — | — | |
| Q2 2022 | +3.6% | — | — | |
| Q1 2022 | +14.6% | — | — | |
| Q4 2021 | +5.1% | — | — | |
| Q3 2021 | +1.4% | — | — | |
| Q2 2021 | +1.1% | — | — | |
| Q1 2021 | -19.4% | — | — | |
| Q4 2020 | -4.7% | — | — | |
| Q3 2020 | -0.8% | — | — | |
| Q2 2020 | +1.6% | — | — | |
| Q1 2020 | -6.2% | — | — | |
| Q4 2019 | +14.8% | — | — | |
| Q3 2019 | -13.5% | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro